Recursion Pharmaceuticals had aligned with the FDA on the design of its registrational Phase 3 trial of REC-4881, an ...
A critical vulnerability dubbed Java4Shell in OpenJDK, the open-source implementation of Java, can allow unauthenticated ...
New Phase 2 REC-4881 data presented at CGA-IGC in an expanded adult population aged 18 years and older show deep, durable polyp burden ...
For the past few days I’ve been testing an impressive open-weight AI coding model called Flint. It suggests that fully recursive self-improvement, or RSI—an exciting and controversial approach that ...
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this ...
Factorial Energy Inc. targets high-value battery markets, leveraging superior performance for early aerospace and drone applications before scaling to automotive. FAC is rated ‘Buy’ based on its ...
Solid-state battery specialist Factorial Energy is teaming up with Mitsui Kinzoku, one of the few companies producing sulfide-based solid electrolytes, to scale up the promising new technology.
This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Regan Peng is an AI founder and former senior tech executive, focused on personal AI, ...
Factorial Funds, a venture firm launched five years ago by former Cruise engineer Sol Bier, has crossed $1 billion in realized profits, according to a letter the firm is sharing with its investors.
For years now Tim Holme has watched the same drama repeat itself roughly once a week. A headline arrives: some laboratory somewhere has cracked the problem, invented the battery of the future, solved ...
BOSTON, Aug. 11, 2026 (GLOBE NEWSWIRE)-- Factorial Energy Inc. ("Factorial") (Nasdaq: FAC), a global leader in solid-state battery technology, today announced financial and business results for the ...
The up-to-$12 billion artificial intelligence (AI) drug discovery collaboration of Recursion, Roche, and its Genentech subsidiary marked a milestone Wednesday when plans were announced for Recursion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results